February 2010 in “Journal of The American Academy of Dermatology” Most patients with alopecia areata in China have patchy hair loss, with total hair loss being less common, and the condition often starts around age 35 and can negatively affect quality of life, especially in more severe cases.
February 2010 in “Journal of The American Academy of Dermatology” The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.
April 2016 in “Journal of The American Academy of Dermatology” Alopecia areata affects quality of life more than androgenetic alopecia.
290 citations,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
218 citations,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
205 citations,
April 2013 in “British Journal of Dermatology” Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
182 citations,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
176 citations,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
164 citations,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
109 citations,
May 2011 in “Dermatologic Therapy” Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.
101 citations,
November 1992 in “Archives of Dermatology” Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.
100 citations,
July 2018 in “Journal of The American Academy of Dermatology” People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.
99 citations,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
95 citations,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
89 citations,
March 2018 in “The Journal of Dermatology” Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.
85 citations,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
72 citations,
July 2014 in “American journal of clinical dermatology” Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.
63 citations,
May 2017 in “American Journal of Clinical Dermatology” People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.
62 citations,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
52 citations,
March 2010 in “British Journal of Dermatology” Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.
46 citations,
August 2019 in “Journal of the European Academy of Dermatology and Venereology” People with hair loss conditions experience more anxiety, depression, and a lower quality of life than those without these conditions.
45 citations,
December 2014 in “Journal of the European Academy of Dermatology and Venereology” Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.
44 citations,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
41 citations,
September 2018 in “Australasian journal of dermatology” No systemic treatment for alopecia areata has strong evidence of effectiveness.